The platelet GP Ib-IX receptor supports platelet adhesion and activation by binding to vWf in the exposed subendothelial matrix. An abnormal GP Ib-IX complex exists in platelet-type or pseudo-von Willebrand disease and has a characteristic increased affinity for soluble vWf resulting in impaired hemostatic function due to the removal of larger vWf multimers from the circulation. Genetic studies within an afflicted family have demonstrated that the disease is linked to a Gly233 -) Val amino acid substitution within the a-subunit of the oligomeric GP Ib-IX complex (Miller, J. L., D.
Introduction
The adhesion of platelets onto an altered vascular surface is an early event in thrombogenesis supported by specific platelet membrane receptors and their adhesive ligands. Among the latter, vWf binds to two sites on the platelet membrane, the GP Ib-IX and the GP IIb-IIIa receptor complexes (1) (2) (3) (4) . vWf as a soluble component of plasma has an unmeasurable affinity for unstimulated circulating platelets, thus, specific mechanisms must be responsible for initiation of the interaction between vWf and platelets at sites of vascular injury. In the temporal sequence of interactions leading to thrombus formation, the recognition of surface-bound vWf by GP lb is the first necessary step leading to irreversible adhesion under high shear stress ( 5) .
It has been proposed that the regulation of vWf binding to GP Ib-IX may depend upon specific functional conformations acquired by the ligand and/or the receptor either as a consequence of rheological conditions or, in the case of vWf, as a result of being surface-bound within the subendothelial matrix (6) (7) (8) . Indeed, the possibility of regulating affinity through conformational changes in vWfhas been recently supported by the demonstration that a single amino acid substitution results in a subtype of von Willebrand disease, type IIB, in which an abnormal soluble vWf molecule has an increased affinity for a normal GP Ib-IX complex (9) . Conversely, structural alterations in the platelet GP Ib-IX complex are presumed to be the underlying molecular basis ofplatelet-type or pseudo-von Willebrand disease in which an aberrant receptor has increased affinity for normal vWf ( 10, 11). Both platelet-type von Willebrand disease and type IIB von Willebrand disease are clinically similar but the underlying molecular bases are different, one resulting from a hyperfunctional ligand (type IIB von Willebrand disease) and the other from a hyperfunctional platelet receptor (platelet-type von Willebrand disease). This implies that conformational changes in both GP Ib and vWf may be relevant to platelet thrombus formation.
A variant GP Ib-IX complex resulting in platelet-type von Willebrand disease has been associated with a single amino acid substitution, Gly233 -* Val, within the a-subunit ofthe GP Ib-IX complex (12) . However, the GP Ib-IX complex is a three-subunit receptor and even though the a-subunit (GP Iba) contains the binding site for vWf, it is not known if the other two subunits of the complex contribute to the in vivo modulation of binding to vWf ( 13, 14) . Thus, without supporting evidence that the other components of the receptor complex are normal, it is impossible to conclude with certainty that the a-subunit containing Val at position 233 is responsible for increased in vivo affinity for vWf. In this report we demonstrate that a GP Iba recombinant analogue containing the Gly233 -> Val substitution displays increased binding affinity for normal vWf. The results provide direct evidence that a GP Iba fragment can functionally mimic the abnormal receptor associated with platelet-type von Willebrand disease and support the concept that conformation changes associated with the a-subunit ofthe GP Ib-IX receptor complex may be an important mechanism in the regulation of hemostasis.
Methods
Construction of recombinant plasmids and generation of stable cell lines. A recombinant plasmid, pMW2, has been previously reported ( 15) and directs the secretion from Chinese hamster ovary (CHO-K 1 )' cells of a GP Iba fragment composed of residues His'-Ala302. This secreted fragment corresponds to a previously characterized 45-kD tryptic fragment from the amino terminus of GP Iba containing the binding site for vWf ( 13, 16, 17) . pMW2 was constructed from a genomic fragment of the GP Iba gene inserted into pCDM8 , a modified version of pCDM8 containing a neomycin resistance gene ( 18) . The secreted GP Iba fragment containing native sequence instrinsically assembles into a conformation recognized by a series of anti-GP Iba monoclonal antibodies and binds von Willebrand factor in the presence of modulators, either ristocetin or botrocetin ( 15) . The monoclonal antibodies used in these studies, LJ-Ibal, LJ-Ibl, LJ-P3, and LI-P19 have been previously described ( 13, 16, 17) . A rabbit antiserum obtained by immunization with a synthetic peptide corresponding to GP Iba residues Gly27'-Glu285 was also used. pMW2/G233V is identical to pMW2 except that the Gly2" codon (GGT) ofpMW2 was changed to a Val233 codon (GTT). Site-directed mutagenesis was performed on uracil-containing template derived from a recombinant filamentous phage containing the GP Iba coding sequence of pMW2 (19) . After mutagenesis, the a-subunit coding sequence was checked by DNA sequence analysis to verify that only codon 233 had been altered. The mutant GP Iba fragment was subsequently cloned into pCDM8ne°.
pMW2 and pMW2/G233V were separately transfected into CHOKl cells using a calcium phosphate transfection procedure (20 antiserum obtained from immunization with the Gly271-Glu285 synthetic peptide. '25I-vWf binding to recombinant GP Iba fragments. Culture medium from cells transformed by pMW2 and pMW2/G233V was assayed for the quantity of GP Iba antigen by reacting with LJ-Iba I or the polyclonal antiserum derived from the Gly271-G0u285 peptide. The relative reactivities of LJ-Iba 1 and the anti-Gly27'-G0u285 serum were similar as assessed by serial twofold dilutions ofthe culture media containing each recombinant fragment. This implies that the Gly233 -I Val substitution has no effect on the epitope(s) recognized by each antibody. In fact, the chosen cell lines from each transformation secreted indistinguishable levels of GP Iba antigen so that dilutions were not required in order to obtain comparable levels of antigen for binding studies. Serum-free culture media for binding analyses was harvested after a 24 h incubation from confluent flasks in which the cells were prewashed three times with DMEM.
The binding assay to evaluate vWf interaction with the recombinant fragments has been described in detail ( 15) . In this assay the receptor fragment is immobilized on a nitrocellulose membrane and the radiolabeled ligand, '25I-vWf, is filtered through the membrane using a vacuum generated by a peristaltic pump. This assay was chosen to mimic the situation ofthe GP Ib-IX-V complex inserted in the platelet membrane, and indeed, '25I-vWf binding to nitrocellulose was shown to be specific for the recombinant GP Iba fragment using monoclonal antibodies that inhibit vWfbinding to platelet GP lb ( 15 ) . In addition, the binding assays are performed under conditions whereby the nitrocellulose is saturated with each recombinant GP Iba fragment, such that, increasing the recombinant fragment concentration does not result in increased vWf binding.
The binding was performed by immobilizing the recombinant fragments onto a nitrocellulose membrane using a commercially available apparatus designed for an enzyme-linked immunofiltration technique (ELIFA; Pierce Chemical Co., Rockford, IL). Culture medium (200 gl) was vacuum-drawn through the nitrocellulose membrane by a peristaltic pump. After binding the culture medium, the binding capacity of the nitrocellulose was saturated by filtering 600 gl of Hepes-BSAbuffer (20 mM Hepes, pH 7.4; 150 mM NaCl; 1% BSA) through the membrane. After this blocking step, a 50-Al mixture of "2'I-vWf with the indicated concentration ofristocetin orbotrocetin(SigmaImmunochemicals, St. Louis, MO) was filtered through the membrane. The vWf was labeled via the iodination procedure of Fraker and Speck (21) . For the ristocetin and botrocetin-dependent binding curves (Fig.   2 ), a final wash of 200 ,d Hepes-BSA buffer was used. For determining the amount of 251I-vWf bound to each sample, a nitrocellulole disc corresponding to each application well was counted in a y-scintiilation spectrometer. Under the described conditions, the binding of 1251-vWf to the GP Iba fragment was not reversible. Thus, we refrained from using Scatchard type analysis to obtain "apparent" dissociation constants and to extrapolate "apparent" maximal binding at saturation. "True" values for these parameters can only be obtained under conditions of equilibrium binding.
Results
Expression ofrecombinant GP Iba analogues. To evaluate the structural and functional consequence of a Gly233 -_ Val substitution within GP Iba, we constructed an expression plasmid, pMW2/G233V, that is identical to the previously reported plasmid, pMW2, except that it contains a glycine to valine codon substitution at position 233. As originally reported ( 15), pMW2 directs the secretion from CHO-Kl cells of a soluble amino-terminal fragment of GP Iba containing residues His'-Ala302. Stable CHO-Kl cell lines were established after transfection with pMW2/G233V and secretion of GP Iba antigen was confirmed by immunoblotting with anti-GP Iba monoclonal antibodies. A panel of conformation-dependent monoclonal antibodies, each recognizing distinct epitopes within the NH2-terminal domain of GP Iba, were tested for their ability to interact with culture media containing the Val233 mutant fragment. The immunoreactivity of media containing the mutant fragment was compared to media taken from cells secreting the normal GP Iba fragment and nontransformed CHO-K1 cells. A nondenaturing dot-blot analysis was used since the epitopes recognized by several of the antibodies are sensitive to denaturation. The results demonstrate that the mutant fragment is secreted at levels similar to the fragment containing normal GP Iba sequence and, with respect to the antibodies tested, the two are immunologically indistinguishable (Fig. 1) .
Functional consequences of a Gly233 --Val substitution. Preliminary studies were performed to determine the amount of ristocetin required to obtain maximal binding at a fixed vWf concentration (Fig. 2, upper graph) . Both the mutant fragment and the fragment with normal sequence had maximal binding when tested with 2 Asg/ml of vWf at 0.7 mg/ml ristocetin.
However, at lower doses of ristocetin (0.2-0.5 mg/ml) the amount of '251-vWf bound to the mutant fragment was markedly increased as compared to vWf bound to the normal fragment. For example, the Gly233 Val mutant fragment bound fourfold more vWf using ristocetin at 0.25 mg/ml. In contrast, vWf binding supported by increasing amounts of botrocetin was essentially identical for both fragments (Fig. 2, lower  graph) .
The apparent enhanced interaction between vWf and the mutant fragment was further investigated by evaluating the effect of increasing vWf concentration on the amount of vWf bound in the presence of different amounts of ristocetin. A representative experiment using 0.34 mg/ml of ristocetin is illustrated in Fig. 3 (upper graph) , demonstrating that the mutant fragment binds more vWf than the control native frag-Culture Medium Figure 1 ment at any concentration of vWf tested. Thus, the Gly233 -Val mutant fragment bound 10-fold more vWfthan the corresponding normal fragment control using 5 ug/ml of vWf and 0.34 mg/ml ofristocetin (Fig. 3, upper graph) . Neither GP Iba fragment was able to bind vWf in the absence of ristocetin. In contrast, using ristocetin at 1 mg/ml both G233V-transformed cells (G233V), or nontransformed CHO-Kl cells. The membranes were dried without washing, and the bound radioactivity was determined as described in Fig. 2 . Background binding obtained using nontransformed CHO-Kl cell supernatant was subtracted from that value obtained using the culture medium from the two transformed cells lines. o, WT; A, G233V.
regardless of the vWf concentration added (Fig. 3, lower  graph) . It is apparent from these assays that the binding curve generated for the mutant fragment, but not the normal fragment, is the same whether ristocetin is used at 0.34 mg/ml or 1 mg/ml (compare the curves shown in the upper and lower graphs of Fig. 3) . Thus, the phenotypic consequence of a Gly233 -> Val substitution in the recombinant fragment is not an increased binding capacity for vWf, but an ability to bind a similar amount of vWf at a lower concentration of ristocetin.
Discussion
Under normal in vivo circumstances, the interaction between vWf and platelet GP Ib-IX is strictly regulated to occur only at those times required for the initiation of hemostasis. As an example of this regulation, soluble plasma vWf has an unmeasurable affinity for circulating platelets, yet the exposure of surface-bound vWfat a site ofvascular injury is a crucial factor for supporting platelet adhesion via the GP Ib-IX complex ( 1, 2, 6) . Two disease states, platelet-type von Willebrand disease and type IIB von Willebrand disease, have suggested that abnormalities in either the receptor or the ligand may support an interaction between soluble vWf and platelets with a sufficient affinity to promote intravascular platelet clumping, thrombocytopenia, and a resulting bleeding disorder.
Relevant to platelet-type von Willebrand disease, Miller et al. ( 12) identified an amino acid change at position 233 of the a-subunit of GP lb that was linked to inheritance of the platelet-type von Willebrand disease phenotype. Indeed, in vitro binding assays and studies using monoclonal antibodies have identified the binding site for vWf to be within the first 293 residues of GP Iba ( 15, 17) , but the possible in vivo role ofthe other subunits ofthe complex, the fl-chain ofGP lb and GP IX, of the a-chain ofGP Ib in modulating and supporting the binding of vWf to the platelet GP Ib-IX complex. The vWfbinding curves generated using the mutant recombinant fragment were similar regardless ofwhether binding was performed with 0.34 mg/ml or 1 mg/ml ristocetin (Fig. 3) 
